← Leaderboards
Jerome A. Zack
University Of California Los Angeles
$38,514,975
Attributed
$43,818,049
Total exposure
25
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$98,970,646 · 29
By mechanism
P30$51,157,800 · 6
P01$23,528,724 · 10
R01$17,533,169 · 7
R37$2,785,604 · 1
U19$1,792,918 · 1
R56$1,595,652 · 2
Top collaborators
- Paul Wender10 shared
- Judith S. Currier6 shared
- Lashonda Spencer6 shared
- Catherine A Blish5 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Paul Wender$20,449,594
- Ren Sun$20,189,518
- Aldons Jake Lusis$39,552,334
- Teresa E Seeman$21,772,630
- Richard Thomas Lebeau$1,047,116
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsAcquired Immunodeficiency SyndromeCellsHiv InfectionsResearch PersonnelIn VitroIn VivoCollaborationsDesignBaseFundingAntiretroviral TherapyVirusCommunicationT-LymphocyteInfectionHumanized MouseMouse ModelGrantServicesImmune SystemLaboratoriesLifeViral
Grant awards (135)
UCLA-CDU CFAR$2,250,002
P30 · FY2025 · AI
Core A -Administrative Core$885,911
P30 · FY2025 · AI · contact PI
Towards HIV eradication: New concepts and potent compounds for PKC-mediated latency reversal$721,067
R01 · FY2025 · AI · contact PI
Natural killer cell engineering to target the HIV reservoir$712,670
R01 · FY2025 · AI · contact PI
UCLA-CDU CFAR$1,950,002
P30 · FY2024 · AI · contact PI
Towards HIV eradication: New concepts and potent compounds for PKC-mediated latency reversal$751,879
R01 · FY2024 · AI · contact PI
Natural killer cell engineering to target the HIV reservoir$747,575
R01 · FY2024 · AI · contact PI
Core A -Administrative Core$704,869
P30 · FY2024 · AI · contact PI
UCLA-CDU CFAR$151,916
P30 · FY2024 · AI · contact PI
UCLA-CDU CFAR$3,209,540
P30 · FY2023 · AI · contact PI
Core A -Administrative Core$1,571,658
P30 · FY2023 · AI · contact PI
Natural killer cell engineering to target the HIV reservoir$760,119
R01 · FY2023 · AI · contact PI
UCLA-CDU CFAR$527,698
P30 · FY2023 · AI · contact PI
Towards HIV eradication: New concepts and potent compounds for PKC-mediated latency reversal$469,113
R01 · FY2023 · AI · contact PI
Core A -Administrative Core$361,151
P30 · FY2023 · AI · contact PI
UCLA-CDU CFAR$3,005,597
P30 · FY2022 · AI · contact PI
Towards HIV eradication: New concepts and potent compounds for PKC-mediated latency reversal$797,798
R56 · FY2022 · AI · contact PI
Natural killer cell engineering to target the HIV reservoir$772,072
R01 · FY2022 · AI · contact PI
Core A -Administrative Core$712,078
P30 · FY2022 · AI · contact PI
Defining Factors Controlling HIV Rebound$1,464,427
P01 · FY2021 · AI · contact PI
Natural killer cell engineering to target the HIV reservoir$798,248
R01 · FY2021 · AI · contact PI
HIV Latency Reversal Through Novel, Potent PKC Modulators$797,854
R56 · FY2021 · AI · contact PI
Impact of engineered immune cells on viral rebound$336,819
P01 · FY2021 · AI · contact PI
Administrative Core$139,120
P01 · FY2021 · AI · contact PI
Palm Springs Symposia on HIV/AIDS$20,000
R13 · FY2021 · AI · contact PI
Defining Factors Controlling HIV Rebound$1,485,132
P01 · FY2020 · AI · contact PI
HIV latency reversal through novel, potent PKC modulators$682,208
R01 · FY2020 · AI · contact PI
Impact of engineered immune cells on viral rebound$338,361
P01 · FY2020 · AI · contact PI
Administrative Core$139,757
P01 · FY2020 · AI · contact PI
Palm Springs Symposia on HIV/AIDS$20,000
R13 · FY2020 · AI · contact PI
Defining Factors Controlling HIV Rebound$1,505,434
P01 · FY2019 · AI · contact PI
HIV latency reversal through novel, potent PKC modulators$679,992
R01 · FY2019 · AI · contact PI
Impact of engineered immune cells on viral rebound$346,250
P01 · FY2019 · AI · contact PI
Administrative Core$143,016
P01 · FY2019 · AI · contact PI
Palm Springs Symposia on HIV/AIDS$20,000
R13 · FY2019 · AI · contact PI
Defining Factors Controlling HIV Rebound$1,525,228
P01 · FY2018 · AI · contact PI
UCLA Center for AIDS Research (CFAR)$1,203,745
P30 · FY2018 · AI · contact PI
HIV latency reversal through novel, potent PKC modulators$641,213
R01 · FY2018 · AI · contact PI
Administrative Core$381,665
P30 · FY2018 · AI · contact PI
Impact of engineered immune cells on viral rebound$350,802
P01 · FY2018 · AI · contact PI
Administrative Core$144,898
P01 · FY2018 · AI · contact PI
Palm Springs Symposia on HIV/AIDS$20,000
R13 · FY2018 · AI · contact PI
UCLA Center for AIDS Research (CFAR)$2,407,486
P30 · FY2017 · AI · contact PI
Defining Factors Controlling HIV Rebound$1,540,000
P01 · FY2017 · AI · contact PI
HIV latency reversal through novel, potent PKC modulators$628,963
R01 · FY2017 · AI · contact PI
Administrative Core$422,845
P30 · FY2017 · AI · contact PI
Impact of engineered immune cells on viral rebound$354,200
P01 · FY2017 · AI · contact PI
Administrative Core$146,301
P01 · FY2017 · AI · contact PI
Palm Springs Symposia on HIV/AIDS$20,000
R13 · FY2017 · AI · contact PI
UCLA Center for AIDS Research (CFAR)$2,571,006
P30 · FY2016 · AI · contact PI
HIV latency reversal through novel, potent PKC modulators$645,378
R01 · FY2016 · AI · contact PI
Administrative Core$562,196
P30 · FY2016 · AI · contact PI
Palm Springs Symposia on HIV/AIDS$20,000
R13 · FY2016 · AI · contact PI
UCLA Center for AIDS Research (CFAR)$2,407,486
P30 · FY2015 · AI · contact PI
Administrative Core$415,423
P30 · FY2015 · AI · contact PI
Eradication of HIV reservoirs in vivo$357,466
U19 · FY2015 · AI · contact PI
UCLA Center for AIDS Research (CFAR)$2,767,328
P30 · FY2014 · AI · contact PI
Administrative Core$419,821
P30 · FY2014 · AI · contact PI
Targeting HIV Reservoirs in vitro and in vivo$385,000
R01 · FY2014 · AI · contact PI
Eradication of HIV reservoirs in vivo$341,337
U19 · FY2014 · AI · contact PI
Generation of Anti-Melanoma T Cells Derived from Human Embryonic Stem Cells$321,862
P01 · FY2014 · CA · contact PI
UCLA Center for AIDS Research (CFAR)$2,848,996
P30 · FY2013 · AI · contact PI
Administrative Core$602,489
P30 · FY2013 · AI · contact PI
HIV Infection of Hematopoietic Stem/Progenitor Cells (HSPC) in Bone Marrow$434,280
R01 · FY2013 · AI · contact PI
Targeting HIV Reservoirs in vitro and in vivo$361,900
R01 · FY2013 · AI · contact PI
Eradication of HIV reservoirs in vivo$353,235
U19 · FY2013 · AI · contact PI
Generation of Anti-Melanoma T Cells Derived from Human Embryonic Stem Cells$288,409
P01 · FY2013 · CA · contact PI
UCLA Center for AIDS Research (CFAR)$2,293,407
P30 · FY2012 · AI · contact PI
Control of Multineage Human ESC Differentiation$1,814,377
P01 · FY2012 · GM · contact PI
HIV Infection of Hematopoietic Stem/Progenitor Cells (HSPC) in Bone Marrow$462,000
R01 · FY2012 · AI · contact PI
Administrative Core$417,074
P30 · FY2012 · AI · contact PI
Targeting HIV Reservoirs in vitro and in vivo$385,000
R01 · FY2012 · AI · contact PI
Eradication of HIV reservoirs in vivo$369,148
U19 · FY2012 · AI · contact PI
Control of Hematopoietic Differentiation by hESCs$334,712
P01 · FY2012 · GM · contact PI
Generation of Anti-Melanoma T Cells Derived from Human Embryonic Stem Cells$308,087
P01 · FY2012 · CA · contact PI
Administrative Core$118,730
P01 · FY2012 · GM · contact PI
UCLA Center for AIDS Research (CFAR)$2,920,591
P30 · FY2011 · AI · contact PI
Control of Multineage Human ESC Differentiation$1,817,922
P01 · FY2011 · GM · contact PI
Administrative Core$615,452
P30 · FY2011 · AI · contact PI
Targeting HIV Reservoirs in vitro and in vivo$385,000
R01 · FY2011 · AI · contact PI
Eradication of HIV reservoirs in vivo$371,732
U19 · FY2011 · AI · contact PI
Control of Hematopoietic Differentiation by hESCs$336,443
P01 · FY2011 · GM · contact PI
Generation of Anti-Melanoma T Cells Derived from Human Embryonic Stem Cells$308,799
P01 · FY2011 · CA · contact PI
Administrative Core$119,390
P01 · FY2011 · GM · contact PI
UCLA Center for AIDS Research (CFAR)$2,675,166
P30 · FY2010 · AI · contact PI
Control of Multineage Human ESC Differentiation$1,839,768
P01 · FY2010 · GM · contact PI
Administrative Core$1,496,322
P30 · FY2010 · AI · contact PI
An in vitro Model for HIV Latency in Primary Cells$364,245
R01 · FY2010 · AI · contact PI
Control of Hematopoietic Differentiation by hESCs$341,539
P01 · FY2010 · GM · contact PI
Generation of Anti-Melanoma T Cells Derived from Human Embryonic Stem Cells$318,349
P01 · FY2010 · CA · contact PI
UCLA Center for AIDS Research (CFAR)$126,000
P30 · FY2010 · AI · contact PI
Administrative Core$121,245
P01 · FY2010 · GM · contact PI
UCLA Center for AIDS Research (CFAR)$2,516,262
P30 · FY2009 · AI · contact PI
Control of Multineage Human ESC Differentiation$1,861,759
P01 · FY2009 · GM · contact PI
Administrative Core$1,407,628
P30 · FY2009 · AI · contact PI
An in vitro Model for HIV Latency in Primary Cells$367,923
R01 · FY2009 · AI · contact PI
Control of Hematopoietic Differentiation by hESCs$346,653
P01 · FY2009 · GM · contact PI
An in vitro Model for HIV Latency in Primary Cells$315,634
R01 · FY2009 · AI · contact PI
Administrative Core$123,101
P01 · FY2009 · GM · contact PI
Control of Multineage Human ESC Differentiation$115,500
P01 · FY2009 · GM · contact PI
UCLA Center for AIDS Research (CFAR)$2,485,000
P30 · FY2008 · AI · contact PI
Control of Multineage Human ESC Differentiation$1,865,822
P01 · FY2008 · GM · contact PI
Administrative Core$1,462,152
P30 · FY2008 · AI · contact PI
Control of Hematopoietic Differentiation by hESCs$380,338
P01 · FY2008 · GM · contact PI
An in vitro Model for HIV Latency in Primary Cells$367,923
R01 · FY2008 · AI · contact PI
Administrative Core$123,200
P01 · FY2008 · GM · contact PI
An in vitro Model for HIV Latency in Primary Cells$375,049
R01 · FY2007 · AI · contact PI
In Vivo Pathogenesis of HIV-1$361,494
R37 · FY2007 · AI · contact PI
Thymic Function and Immune Reconstitution for AIDS$225,029
R21 · FY2007 · AI · contact PI
An in vitro Model for HIV Latency in Primary Cells$386,250
R01 · FY2006 · AI · contact PI
Immune Reconstitution Following HIV Infection$372,291
R01 · FY2006 · AI · contact PI
In Vivo Pathogenesis of HIV-1$372,291
R37 · FY2006 · AI · contact PI
Thymic Function and Immune Reconstitution for AIDS$231,750
R21 · FY2006 · AI · contact PI
Immune Reconstitution Following HIV Infection$381,250
R01 · FY2005 · AI
In Vivo Pathogenesis of HIV-1$381,250
R37 · FY2005 · AI
CD4 EXPRESSION ON CD8+ CELLS$343,125
R01 · FY2005 · AI
Immune Reconstitution Following HIV Infection$381,250
R01 · FY2004 · AI
In Vivo Pathogenesis of HIV-1$381,250
R37 · FY2004 · AI
CD4 EXPRESSION ON CD8+ CELLS$343,125
R01 · FY2004 · AI
Immune Reconstitution Following HIV Infection$381,250
R01 · FY2003 · AI
In Vivo Pathogenesis of HIV-1$381,250
R37 · FY2003 · AI
CD4 EXPRESSION ON CD8+ CELLS$343,125
R01 · FY2003 · AI
Immune Reconstitution Following HIV Infection$381,979
R01 · FY2002 · AI
CD4 EXPRESSION ON CD8+ CELLS$343,688
R01 · FY2002 · AI
IN VIVO PATHOGENESIS OF HIV1$311,679
R37 · FY2002 · AI
CORE--NUDE/SCID-HU MOUSE$181,487
P01 · FY2002 · CA
CORE--MOUSE/HUMAN CHIMERA$129,540
P30 · FY2002 · AI
CD4 EXPRESSION ON CD8+ CELLS$344,250
R01 · FY2001 · AI
IN VIVO PATHOGENESIS OF HIV1$302,602
R37 · FY2001 · AI
CORE--MOUSE/HUMAN CHIMERA$129,540
P30 · FY2001 · AI
CORE--MOUSE/HUMAN CHIMERA$0
P30 · FY2001 · AI
IMMUNE RECONSTITUTION AND GENE TRANSFER IN SCID/HU MICE$317,135
R01 · FY2000 · AI
IN VIVO PATHOGENESIS OF HIV1$293,788
R37 · FY2000 · AI
CORE--NUDE/SCID-HU MOUSE$181,487
P01 · FY2000 · CA
CORE--MOUSE/HUMAN CHIMERA$142,758
P30 · FY2000 · AI